01-why-is-prior-authorizatio-broken-in-oncology

Why Is Prior Authorization Broken in Oncology

AdobeStock_505155628

Why Is Prior Authorization Broken in Oncology, and What Is Starling Oncology Doing About It?

A cancer diagnosis leaves little room to wait. Oncologists build treatment plans around clinical evidence and the knowledge that every week can shape a patient’s outcome. That careful decision then meets prior authorization, a process designed for routine care rather than oncology’s complexity. Fragmented prior authorization systems, inconsistent criteria and reviewers without oncology training turn a clinical judgment call into an administrative holding pattern.

Federal regulators have acknowledged the problem, with the Centers for Medicare and Medicaid Services (CMS) requiring faster decision timelines for affected payers. While faster timelines address speed, closing the deeper gap depends on connecting decision-making and utilization management, which have operated as separate systems. A different approach is starting to change that.

Prior Authorization in Oncology Was Never Built for Modern Complexity

The reasons why prior authorization is broken in oncology rarely trace back to one slow payer or a single decision. The deeper issue is structural. Clinical decision-making and utilization management have operated as separate systems for years, and every request absorbs the cost of that disconnect. The results are delays and errors in the delivery of care.

Practices must navigate fragmented prior authorization systems, juggling a different portal for each payer while tracking and following up on each case separately. Because the timing of cancer treatment carries clinical weight, inefficiencies that

other specialties tolerate become something else entirely in oncology.

The Disconnect Between Treatment Decisions and Authorization

Oncologists build treatment plans around National Comprehensive Cancer Network (NCCN) guidelines and other evidence-based pathways. That clinical reasoning must then be manually re-translated into a payer’s authorization system. Providers often submit a request before learning whether the regimen will be recognized, auto-approved, or flagged for a lengthy peer-to-peer review. Guideline concordance is often confirmed only after a denial forces the issue. 

The Community Oncology Alliance (COA) has taken a clear stance on this problem, arguing that treatments following recognized pathways or clinical guidelines merit exemption from authorization requirements.

Despite that widespread agreement, the practice persists and the disconnect extends to who reviews these decisions in the first place. Sixteen percent of physicians say reviewers in peer-to-peer consultations often or always have the appropriate qualifications, while 35% say prior authorization criteria are rarely or never evidence-based.

AdobeStock_1341979123

Clinical and Administrative Burdens of Prior Authorization

Three costs compound once a request enters the system:

  1. Treatment delays with clinical consequences: Ninety-two percent of radiation oncologists report that prior authorization delays cancer treatment, with 30% linking the process to a serious complication such as hospitalization. Seven percent report a case that ended in a patient’s death.
  2. Administrative burden on oncology practice teams: Physicians and staff spend roughly 13 hours a week completing an average of 40 requests, and 60% of practices now employ staff who work almost exclusively on prior authorization. Nearly all physicians — 94% — say the process contributes to burnout.
  3. A black box after submission: Once a request is submitted, practices typically rely on follow-up calls and repeated portal checks to learn where it stands. Radiation oncologists offer the clearest sign that this friction rarely reflects legitimate clinical disagreement: denied requests are overturned on appeal 73% of the time.

How Prior Authorization Impacts Patient Outcomes

More than one in four physicians, 26%, say prior authorization has caused a serious adverse event for a patient in their care, including:

  • Hospitalization in 20% of cases.
  • A life-threatening complication in 22% of cases.
  • Death or permanent disability in 8% of cases.

The same survey found that 79% of physicians believe prior authorization at least sometimes leads patients to abandon treatments altogether.

For oncology providers, these figures describe real patients who followed a guideline-concordant plan only to watch it stall in review. Regulators have started responding. Federal rules that took effect in 2026 require impacted payers to decide on urgent requests within 72 hours and standard requests within seven calendar days. That timeline addresses speed, but the deeper fix still depends on connecting decision-making and utilization management as one system.

How Starling Nexus™ Was Built to Address It

Effective utilization management should help patients start appropriate cancer care sooner, not create another administrative hurdle during a time that’s already stressful. Starling Nexus™ was built with that goal in mind, reflecting the day-to-day challenges physicians and care teams face.

The organization behind it employs more than 400 clinicians and operates more than 100 clinics and a growing five-state network built on a value-based approach to cancer care that prioritizes patient outcomes and quality of care over volume. Starling Nexus™ extends the same value-based oncology technology platform logic into the authorization process itself. The aim is to improve decision speed and the quality of care patients receive.

Connecting Clinical Decision Support and Utilization Management

Starling Nexus™ connects clinical decision-making and utilization management within a single system, replacing the disconnect that has defined oncology prior authorization. Instead of making a treatment decision in one system and then re-entering it into a separate payer portal, providers see pathways surfaced during order-building, with guideline-concordance visible before a request is submitted. 

 

Built specifically as oncology utilization management software, Starling Nexus™ brings several capabilities into one place:

  • Real-time clinical decision support: Evidence-based pathways appear directly within the ordering workflow, so providers see guideline concordance before they submit.
  • A single sign-on: Practices consolidate what were once separate payer logins into a single sign-on scoped to their organization.
  • Order-status tracking: Once a request is submitted, providers can view its status directly, a direct answer to the black box effect.

Prioritizing Guideline-Concordant Care

Recommended pathways used without modification can move through a more streamlined authorization process. Nonstandard treatments, including regimens that are custom-built or meaningfully modified, can be routed for additional clinical review. Providers gain clearer insight into the path a request is likely to follow, reducing the guesswork that currently makes every authorization something of a gamble.

This turns the COA’s long-standing position that authorization shouldn’t apply to guideline-concordant care into a daily workflow reality. Clinical review for a genuinely nonstandard case still matters, and that review is now reserved for situations where it adds value.

Looking ahead, Starling Nexus™ is designed to expand into ancillary services such as pharmacy and clinical trials. This extends that same logic across more cancer treatments, including the clinical trials work already underway across the network.

Connect With Starling Oncology

Oncology prior authorization problems are well-documented, and Starling Oncology has built a dedicated infrastructure to ease the administrative burden on oncology practice teams, changing oncology for the better, one workflow at a time. Starling Nexus™ brings evidence-based pathways and utilization management into one workflow, so practices spend less time on paperwork and more time with patients.

If your practice is navigating the same friction, connect with our team to learn how Starling Nexus™ fits into your daily workflow. And if you have a patient who could benefit from Starling Oncology’s evidence-based, value-based cancer care model focused on quality care and patient outcomes, referring a patient is straightforward, and our coordinators handle the next steps.

Start Today